by palligoelme@gmail.com | Mar 15, 2025 | Clinical Trials
This interview highlights recent findings on roflumilast cream 0.05% for patients aged 2 to 5 years with mild to moderate atopic dermatitis. This interview highlights recent findings on roflumilast cream 0.05% for patients aged 2 to 5 years with mild to moderate...
by palligoelme@gmail.com | Mar 15, 2025 | Clinical Trials
Nivolumab elicited PR/CRs in all patients treated with resectable dMMR endometrial cancer and no patients experienced disease recurrence during follow-up. Nivolumab elicited PR/CRs in all patients treated with resectable dMMR endometrial cancer and no patients...
by palligoelme@gmail.com | Mar 15, 2025 | Clinical Trials
A phase 2 trial found that pembrolizumab plus pemetrexed met its objective response rate primary end point. A phase 2 trial found that pembrolizumab plus pemetrexed met its objective response rate primary end point.
by palligoelme@gmail.com | Mar 14, 2025 | Clinical Trials
Carfilzomib, lenalidomide, and dexamethasone results from the real world continued to show effective responses and a tolerable safety profile. Carfilzomib, lenalidomide, and dexamethasone results from the real world continued to show effective responses and a...
by palligoelme@gmail.com | Mar 14, 2025 | Clinical Trials
Multiple myeloma treatment is advancing with the advent of bispecific antibody drugs, which use the patient’s T cells to fight the disease. Myeloma Center physicians and researchers Carolina Schinke, M.D., and Samer Al Hadidi, M.D., M.S., are leading clinical...
by palligoelme@gmail.com | Mar 14, 2025 | Clinical Trials
Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept pancreatic cancer at bay in preclinical models for significantly longer than the same targeted therapy by itself, according to researchers from...
